ACIP Recommends Use Of New Monoclonal Antibody Against RSV In Babies

STAT (6/26, Branswell, Subscription Publication) reports the CDC’s Advisory Committee on Immunization Practices “voted Thursday to recommend the use of a new monoclonal antibody against RSV in babies,” Merck’s clesrovimab-cfor (Enflonsia). The therapy, “given to babies under 8 months of age entering their first RSV season, is the second product of this kind to enter the market, joining Sanofi and AstraZeneca’s Beyfortus [nirsevimab-alip] in the RSV toolkit.” According to STAT, “the monoclonal antibody injection was shown to reduce the rate of medically attended lower respiratory infection caused by RSV by over 60% and cut the incidence of RSV hospitalization by over 84%.” The treatment was “approved by the Food and Drug Administration in early June.”